BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis
BRCA1- und BRCA2-Mutationen und Wirksamkeit einer pembrolizumab-basierten neoadjuvanten Chemotherapie bei triple-negativem Mammakarzinom: multizentrische Real-World-Analyse
Journal of Clinical Medicine · 14.12.2025 · 14 (24) · 8854
DOI: 10.3390/jcm14248854 ↗Auf einen Blick
Bei 184 Patient:innen mit TNBC war die pCR unter pembrolizumab-basierter NACT bei BRCA1/2-mutierten Tumoren häufiger als bei Wildtyp-Tumoren. Der Unterschied zeigte nur einen Trend.
Fragestellung
Ist der pCR bei TNBC unter pembrolizumab-basierter neoadjuvanter Chemotherapie mit dem BRCA1/2-Mutationsstatus assoziiert?
Methode
Retrospektive multizentrische Analyse von 184 Patient:innen mit Stadium II–III TNBC in 11 italienischen Zentren; Behandlung nach KEYNOTE-522; BRCA1/2 per Next-Generation-Sequenzierung.
Ergebnisse
pCR: 80,0 % bei BRCA1-Mutation, 75,0 % bei BRCA2-Mutation, 61,1 % bei Wildtyp. Gepoolt: 78,4 % vs. 61,1 %; OR 2,17 (95 %-KI 1,01–4,97; p = 0,056).
Einschränkungen
Retrospektiv; keine Vergleichsanalyse zu Toxizität oder Überleben; begrenztes Follow-up.
Schlussfolgerung der Autor:innen
In dieser real-world Kohorte zeigten TNBC-Patient:innen mit BRCA1/2-Mutationen einen Trend zu höheren pCR-Raten unter pembrolizumab-basierter NACT als Wildtyp-Tumoren.
Kernaussagen
- pCR häufiger bei BRCA1/2-mutierten als bei Wildtyp-Tumoren
- Gepoolt: 78,4 % vs. 61,1 %; OR 2,17
- Keine Analyse zu Toxizität oder Überleben
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.12.2025. Verfasst von Palma Fedele und 17 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Dario Camberlingo Hospital, Francavilla Fontana, 72021 Brindisi, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Pembrolizumab has reshaped the neoadjuvant treatment landscape for triple-negative breast cancer (TNBC). However, the influence of BRCA1/2 mutational status on the efficacy of chemo-immunotherapy remains unclear, particularly in real-world settings. Since BRCA-mutated tumors exhibit homologous recombination deficiency (HRD) and high genomic instability, they may be more immunogenic and responsive to immune checkpoint inhibitors. This multicenter study investigated the association between BRCA1/2 mutations and pathologic complete response (pCR) in TNBC patients treated with pembrolizumab-based neoadjuvant chemotherapy (NACT).
Methods
We retrospectively analyzed 184 patients with stage II–III TNBC treated between 2021 and 2024 across eleven Italian oncology centers. All received pembrolizumab combined with platinum- and taxane-based NACT followed by anthracyclines, according to the KEYNOTE-522 regimen. Germline BRCA1/2 status was determined by next-generation sequencing. The primary endpoint was pCR, defined as ypT0/is ypN0. Fisher’s exact test and logistic regression models were used to assess associations between clinical–pathological variables and pCR.
Results
Among 184 patients, 25 (13.6%) harbored BRCA1 mutations, 12 (6.5%) BRCA2 mutations, and 147 (79.9%) were wild-type. pCR was achieved in 80.0% of BRCA1-mutated, 75.0% of BRCA2-mutated, and 61.1% of wild-type tumors. When pooled, BRCA1/2-mutated cases showed a higher likelihood of achieving pCR (78.4% vs. 61.1%; odds ratio [OR] = 2.17; 95% CI 1.01–4.97; p = 0.056). High tumor-infiltrating lymphocytes (≥30%) were also associated with increased pCR rates. The frequency of BRCA mutations (20.1%) was consistent with that reported in major TNBC series. No comparative analysis of toxicity or survival outcomes was performed due to the retrospective design and limited follow-up.
Conclusions
In this multicenter real-world cohort, TNBC patients carrying BRCA1/2 mutations exhibited a trend toward higher pCR rates with pembrolizumab-based NACT compared with wild-type tumors. These findings suggest enhanced chemosensitivity and immune responsiveness in BRCA-deficient disease, warranting further validation in larger prospective studies with survival endpoints.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oncology Unit, Dario Camberlingo Hospital, Francavilla Fontana, 72021 Brindisi, Italy.
- S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
- U.O. Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, Italy.
- Breast Care Unit, University Hospital Consortium Policlinico of Bari, 70124 Bari, Italy.
- Oncology Unit, Fondazione "Casa Sollievo della Sofferenza", IRCCS, San Giovanni Rotondo, 71013 Foggia, Italy.
- Oncology Unit, San Paolo Hospital, 70123 Bari, Italy.
ORCID-Profile: Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Stefania Luigia Stucci, Marianna Giampaglia, Gennaro Gadaleta-Caldarola
Zitieren
APA
Fedele, P., Rizzo, A., Landriscina, M., Stucci, S. L., Morritti, M., Giuliani, F., Moraca, L., Cairo, G., Ardito, R., Giampaglia, M., Bilancia, D., Melaccio, A., Terenzio, A., Gnoni, A., Licchetta, A., Fumai, F., Lanotte, L., & Gadaleta-Caldarola, G. (2025). BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Journal of Clinical Medicine, 14(24), 8854. https://doi.org/10.3390/jcm14248854
Vancouver
Fedele P, Rizzo A, Landriscina M, Stucci SL, Morritti M, Giuliani F, et al. BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. Journal of Clinical Medicine. 2025;14(24):8854. doi:10.3390/jcm14248854
BibTeX
@article{Fedele2025,
author = {Fedele, Palma and Rizzo, Alessandro and Landriscina, Matteo and Stucci, Stefania Luigia and Morritti, Maria and Giuliani, Francesco and Moraca, Lucia and Cairo, Giuseppe and Ardito, Raffaele and Giampaglia, Marianna and Bilancia, Domenico and Melaccio, Assunta and Terenzio, Antonella and Gnoni, Antonio and Licchetta, Antonella and Fumai, Federica and Lanotte, Laura and Gadaleta-Caldarola, Gennaro},
title = {BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {24},
pages = {8854},
doi = {10.3390/jcm14248854}
}
EUVIMED